Semaglutide vs Retatrutide – approved medicine vs investigational triple agonist

This page compares Semaglutide and Retatrutide. It does not provide dosing guidance or treatment recommendations.

The asymmetry that defines this comparison

Most comparison pages weigh two things of roughly the same kind. This one cannot. Semaglutide is an approved medicine sold under three brand names, each with an FDA-approved label, and it has been tested against hard clinical endpoints — heart attacks, strokes, kidney failure, liver histology — in trials enrolling tens of thousands of people. Retatrutide, developmental code LY3437943, has never been approved by any regulator anywhere for any indication. Its legitimate supply exists only inside Eli Lilly’s clinical trials.

That gap is the single most important fact on this page, and it does not get smaller because retatrutide’s headline weight number is bigger. Nearly all the public interest in retatrutide traces to one figure — a mean 24.2% body-weight reduction in a phase 2 trial — set against semaglutide’s 14.9%. Those two numbers come from different trials, in different populations, over different durations, and placing them side by side is arithmetic, not evidence. The sections below take that comparison apart.

Head to head at a glance

One receptor versus three

Semaglutide is a modified analog of GLP-1, the intestinal hormone released after eating. Two engineering changes define it: a substitution that protects it from the enzyme DPP-4, and a fatty-diacid chain that binds it to albumin, stretching its half-life from roughly two minutes to roughly one week. Acting at GLP-1 receptors in the pancreas, gut and brain, it increases glucose-dependent insulin secretion, suppresses glucagon when glucose is high, slows gastric emptying, and reduces hunger.

Retatrutide is a single peptide engineered to hit three receptors at once. Two of them — GLP-1 and GIP — are the pair that tirzepatide already covers. The third, the glucagon receptor, is the novel arm. Glucagon signaling increases energy expenditure and pushes the liver to oxidise fat, layering a “burn more” mechanism on top of the class’s “eat less” pharmacology. That is the leading explanation for retatrutide’s unusually deep effects on both body weight and liver fat.

It is also a balancing act, because glucagon raises blood glucose. A triple agonist has to carry enough incretin activity to keep glycemic control moving the right way. The phase 2 diabetes trial (n=281, 36 weeks) suggests the balance holds: HbA1c fell 2.02 percentage points at the 12 mg dose, against 0.01 for placebo and 1.41 for dulaglutide (Rosenstock et al., The Lancet 2023).

The weight numbers, and what comparing them does not tell you

In STEP 1, a phase 3 trial of 1,961 adults with overweight or obesity, 2.4 mg weekly semaglutide produced a mean body-weight change of −14.9% at 68 weeks versus −2.4% for placebo, with 86.4% of the semaglutide group losing at least 5% (Wilding et al., NEJM 2021).

In retatrutide’s phase 2 obesity trial, 338 adults were randomised across a dose ladder for 48 weeks. Mean body-weight change was −8.7% at 1 mg, −17.1% at 4 mg, −22.8% at 8 mg and −24.2% at 12 mg, against −2.1% for placebo. At the 12 mg dose, 83% of participants lost at least 15% of body weight. The trajectory is worth noting: the 12 mg arm was at −17.5% at the 24-week primary endpoint and −24.2% by 48 weeks, so weight was still falling steeply through the second half of the study (Jastreboff et al., NEJM 2023).

Setting −24.2% against −14.9% is a cross-trial comparison, and a cross-trial comparison is not head-to-head evidence. The two trials differ in almost every way that matters: 338 participants versus 1,961; 48 weeks versus 68; a dose-ranging phase 2 versus a pivotal phase 3; different sites, eras, run-in procedures and statistical estimands. Phase 2 effect sizes also have a long history of shrinking when programmes scale into phase 3 populations with broader eligibility and higher dropout. And the comparison is sensitive to which retatrutide arm you pick — the 1 mg arm’s −8.7% sits well below semaglutide’s STEP 1 result.

The one phase 3 retatrutide efficacy result published so far is in a different population. TRANSCEND-T2D-1 randomised 537 adults with type 2 diabetes to 4, 9 or 12 mg weekly for 40 weeks: HbA1c fell 1.94 percentage points at 12 mg versus 0.81 for placebo, and body weight fell 15.3% versus 2.6% (Bajaj et al., The Lancet 2026). Weight loss is typically smaller in diabetes populations than in obesity populations, so that figure is not directly comparable to either the phase 2 obesity number or to STEP 1.

What only semaglutide has: outcome data

Weight and HbA1c are intermediate endpoints. The evidence that separates these two compounds most sharply is the category where retatrutide has nothing yet — trials measuring whether people have fewer heart attacks, less kidney failure, or better liver histology.

• Heart. SELECT enrolled 17,604 adults with obesity and established cardiovascular disease but without diabetes, and found a 20% relative reduction in major adverse cardiovascular events: hazard ratio 0.80 (95% CI 0.72–0.90) (NEJM 2023). SUSTAIN-6 had already shown a hazard ratio of 0.74 in type 2 diabetes (NEJM 2016).
• Kidney. FLOW (n=3,533, diabetic kidney disease) reported a 24% lower risk of major kidney disease events, hazard ratio 0.76 (95% CI 0.66–0.88) (NEJM 2024).
• Liver. In biopsy-confirmed NASH, 0.4 mg daily semaglutide produced resolution of steatohepatitis in 59% versus 17% on placebo, though the fibrosis endpoint was not met (Newsome et al., NEJM 2021).

Retatrutide’s liver data are genuinely striking but sit a tier lower on the endpoint hierarchy. In a 98-participant phase 2a substudy in metabolic dysfunction-associated steatotic liver disease, relative liver-fat content fell 81.4% at 8 mg and 82.4% at 12 mg at 24 weeks, and 86% of the 12 mg group reached normal liver fat (Sanyal et al., Nature Medicine 2024). That is an imaging endpoint in 98 people, not biopsy histology and not a clinical outcome.

The retatrutide trial built to close this gap is TRIUMPH-Outcomes (NCT06383390), an event-driven phase 3 study of roughly 10,000 participants with cardiovascular disease or chronic kidney disease, listed as active and not recruiting with a completion date in 2029. Until it reports, retatrutide has no cardiovascular or kidney outcome evidence of any kind.

Safety themes

Both compounds share the incretin class’s dominant tolerability problem. On the Wegovy label, 73% of injection-treated adults in the weight-reduction trials reported a gastrointestinal adverse reaction versus 47% on placebo — nausea 44% versus 16%, diarrhea 30% versus 16%, vomiting 25% versus 6%. Severe gastrointestinal reactions occurred in 4.1% versus 0.9%, and permanent discontinuation for a gastrointestinal reaction in 4.3% versus 0.7% (Wegovy prescribing information). Retatrutide’s phase 2 obesity trial likewise reported gastrointestinal events as the most common adverse effects, dose-related, mostly mild to moderate, and partly mitigated by starting at 2 mg rather than 4 mg.

Where they diverge is in what has been characterised. Semaglutide carries a boxed warning for thyroid C-cell tumors seen in rodents, with an associated contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN 2 (Ozempic label), plus labeled warnings covering pancreatitis, gallbladder disease and dehydration-related kidney injury, and a documented retinopathy signal from SUSTAIN-6 (hazard ratio 1.76, 95% CI 1.11–2.78). Retatrutide’s distinctive trial finding is a dose-dependent increase in heart rate that peaked at 24 weeks and declined thereafter — watched closely because glucagon-receptor agonism can raise heart rate beyond what GLP-1 drugs do alone.

The asymmetry is not that retatrutide looks safer. It is that retatrutide has no label, so there is no boxed warning, no contraindication list, no pregnancy section and no post-marketing surveillance to compare against. Absence of a characterised risk profile is absence of characterisation, not absence of risk.

A label versus a trial protocol

Semaglutide’s dosing is defined by prescribing information. All the labeled products follow one pattern: treatment begins at a low, deliberately sub-therapeutic 0.25 mg once weekly and escalates roughly every four weeks toward a maintenance dose — up to 2 mg weekly on the Ozempic label and 2.4 mg weekly on the Wegovy label. The ramp exists purely for tolerability. Exact titration steps and adjustment rules live in the official labels and are individualised by the prescriber.

Retatrutide has no approved dose at all, so the only numbers available describe how trials were designed. The phase 2 obesity study started participants at 2 mg or 4 mg weekly and escalated stepwise to randomised maintenance doses of 1, 4, 8 or 12 mg across 48 weeks; TRANSCEND-T2D-1 evaluated 4, 9 and 12 mg weekly over 40 weeks. Those protocols also embed heart-rate monitoring, glycemic measurement and adverse-event capture that have no counterpart outside a trial. Whether any of those doses becomes an approved regimen is a question for regulators, and the published data do not settle it.

Availability and supply

Semaglutide reaches patients as a regulated pharmacy product in fixed-dose pens. A parallel unapproved market exists alongside it, and the FDA has documented specific problems there: some compounders have used salt forms — semaglutide sodium and semaglutide acetate — that are different active ingredients from the approved drug, and the agency has received multiple adverse-event reports, some requiring hospitalisation, tied to dosing errors with compounded injectable semaglutide (FDA).

For retatrutide the situation is categorically different, and starker. There is no pen, no pharmacy vial, no authorised generic and no approved reference product anywhere in the world. The manufacturer supplies it to no one outside its trials. Every vial sold online under the name “retatrutide” is therefore an unapproved gray-market product whose identity, concentration, purity and sterility no regulator has verified — an unverified substance standing in for a drug that is itself incompletely characterised.

The head-to-head trial that is actually running

A direct comparison does exist — it just has not reported. TRANSCEND-T2D-2 (NCT06260722) is a phase 3, randomised, open-label study of roughly 1,250 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor, randomising them to two retatrutide dose levels or to semaglutide, with change in HbA1c as the primary endpoint. It is listed as active and not recruiting, with a completion date in 2027.

That trial is the standard this comparison should eventually be judged against. Until it publishes, any claim that retatrutide outperforms semaglutide rests on subtracting one trial’s number from another’s — and even then it will answer a glycemic question in a diabetes population, not the weight-loss question most readers arrive with. The broader phase 3 picture includes the completed TRIUMPH obesity trials (TRIUMPH-1, n=2,335 and TRIUMPH-3, n=1,946), whose results will make the weight comparison far more concrete than it is today.

One more thing both compounds share: the effect depends on continued treatment. In STEP 4, participants switched to placebo after a 20-week run-in regained 6.9% of body weight while those continuing semaglutide lost a further 7.9% (JAMA 2021). Trials in this class treat these drugs as chronic therapy rather than a course, and retatrutide’s phase 3 programme includes its own dedicated weight-maintenance study on the same premise (NCT06859268, n=643).

How to dive deeper

• Semaglutide overview · benefits · side effects · dosing education · research
• Retatrutide overview · benefits · side effects · dosing education · research
• Related comparisons: semaglutide vs tirzepatide · tirzepatide vs retatrutide · compare hub
• Background questions: semaglutide vs research peptides for weight loss · what peptide acts like Ozempic · top peptides for weight loss · are GLP-1 peptides safe long term · regaining weight after stopping

References & searches

Every claim above links its primary source. To check the wider literature yourself:

• PubMed search: retatrutide semaglutide
• ClinicalTrials.gov search: retatrutide
• DailyMed: Wegovy (semaglutide) prescribing information